相关实验视频
Updated: May 9, 2025
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.3K
梅波利祖马布可以预防COPD恶化,具有eosinophilic表现型
Frank C Sciurba1, Gerard J Criner2, Stephanie A Christenson3
1Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh.
The New England journal of medicine
|April 30, 2025
概括
在患有慢性阻塞性肺病 (COPD) 和eosinophilic炎症的患者中,梅波利祖马布显著降低了恶化. 这种生物疗法为严重的COPD恶化提供了一个新的治疗选择.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性阻塞性肺病 (COPD) 影响全球数以百万计的人,其中有一部分人经历了eosinophilic炎症.
- 互乐金-5 (IL-5) 是一种关键的细胞因子,在COPD中驱动着eosinophilic炎症.
- 梅波利祖马布向IL-5,为特定的COPD患者群体提供潜在的治疗策略.
研究的目的:
- 评估梅波利祖马布作为COPD患者的补充疗法的疗效,这些患者有过恶化病史和血中乙氨基酸细胞升高.
- 评估梅波利祖马布对中度至重度恶化的发生率的影响.
- 调查二次终点,包括时间到第一次恶化,生活质量和症状负担.
主要方法:
- 一个第三阶段,双盲,随机,安慰剂对照试验.
- 804名患有慢性慢性肺炎和血中乙氨基酸细胞计数≥300细胞/μL的患者每4周服用梅波利祖马布 (100毫克) 或安慰剂,每4周服用一次,持续52-104周.
- 主要终点:中度或严重恶化的年率.
主要成果:
- 与安慰剂相比,梅波利祖马布显著降低了中度或严重恶化的年率 (0.80对1.01事件/年;P=0.01).
- 梅波利祖马布的第一次中度或严重恶化的时间显着更长 (中位数为419 vs. 321天;P=0.009).
- 在生活质量或症状测量方面没有发现显著差异;两组之间不良事件概况相似.
结论:
- 梅波利祖马布治疗,当添加到三重吸入疗法时,有效降低了COPD患者中度至重度恶化率.
- 这些发现支持mepolizumab作为一种向治疗,用于减少特定COPD亚群中的恶化.
- 进一步的研究可能会探索长期结果和成本效益.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
117
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
117
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
151
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
151
01:19Antiasthma Drugs: Leukotriene Modifiers
148
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
148
01:17Drugs Used in Lower Respiratory Disorders: Overview
242
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
242
01:24Antiasthma Drugs: Methylxanthines
105
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
105
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K